MET and hepatocellular carcinoma: Cabozantinib, another multiple kinase inhibitor with most potent inhibition of c-Met, was recently shown to improve median overall survival from 8.0 to 10.2 months as a second line agent in the CELESTIAL phase III trial of HCC.61 Taken all together, we postulated combination of sorafenib with cabozantinib will be likely to improve the first line systemic therapeutic efficacy.